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The relevance of gemcitabine timing for chronotherapeutic optimisation was investigated. Healthy mice received multiple doses of
gemcitabine (120, 160 or 200mgkg
 1injection (inj)
 1) at one of six circadian times (3, 7, 11, 15, 19 or 23h after light onset – HALO)
on days 1, 4, 7 and 10 or a single dose of gemcitabine (400mgkg
 1) at 11 or 23 HALO7cisplatin (5mgkg
 1 at 1min, 4 or 8h later).
Mice bearing Glasgow osteosarcoma received multiple doses of gemcitabine (200mgkg
 1inj
 1) at 11 or 23 HALO7cisplatin
(5mgkg
 1inj
 1 at 1min or 4h later) on days of 10, 13, 16 and 19 following tumour inoculation. A circadian rhythm in body weight
loss was statistically validated, with 1030 HALO corresponding to the least toxic time (95% CL, 0800 to 1300). Gemcitabine dosing
produced least body weight loss and least neutropenia after injection at 11 vs 23 HALO, whether the drug was given alone or with
cisplatin (P¼0.001). Gemcitabine–cisplatin tolerability was improved by dosing gemcitabine at 11 HALO and CDDP at 15 HALO
(Po0.001). The administration of this schedule to tumour-bearing mice increased median survival three-fold as compared to
treatments where both drugs were given simultaneously at 11 or 23 HALO (P¼0.02). The optimal schedule would correspond to
the delivery of gemcitabine upon awakening and cisplatin near mid-activity in cancer patients.
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Gemcitabine (20,20-difluoro-20-deoxycytidine) is a deoxycytidine
analogue that exerts its antitumour activity via multiple mechan-
isms of action. Gemcitabine undergoes intracellular phosphoryla-
tion to the active metabolites gemcitabine diphosphate and
gemcitabine triphosphate, leading to inhibition of ribonucleotide
reductase and incorporation of gemcitabine triphosphate into
DNA and RNA (Xu and Plunkett, 1992; Ruiz van Haperen et al,
1993). It is active against non-small-cell lung cancer, pancreatic
cancer, breast cancer and ovarian cancer (Abratt et al, 1994; Lund
et al, 1994; Carmichael et al, 1995, 1996). A review of gemcitabine
safety profile establishes this drug as a relatively safe antimetabo-
lite, with adverse events that generally are manageable and
reversible, rarely leading to discontinuation of the drug. Of 979
patients included in an overall safety database, less than 1%
discontinued treatment due to haematological, gastrointestinal,
hepatic, or other symptomatic events such as fever, oedema, rash
or alopecia (Data on file. Eli Lilly & Co., Indianapolis, IN, USA).
However, reports of severe and sometimes fatal lung or capillary
toxicities have been observed sporadically, while myelosuppres-
sion is the dose-limiting toxicity (Kaye, 1994; De Pas et al, 2001;
Rosado et al, 2002).
Combination chemotherapy, particularly cisplatin (CDDP)-
based regimes, results in higher response rates as compared to
single-agent chemotherapy. Preclinical studies have shown addi-
tive and synergistic effects of gemcitabine and CDDP in
combination. Gemcitabine increases the formation of DNA-
platinum adducts, while CDDP increases the incorporation of
gemcitabine into DNA-platinum adducts (van Moorsel et al, 1999a;
Peters et al, 2000). This combination has shown significant activity
in a number of tumour types and has become a standard regime in
advanced lung cancer (Rinaldi et al, 2000; Sandler et al, 2000).
However, increased toxicities resulted from combining gemcita-
bine with CDDP or carboplatin have been reported (Rinaldi et al,
2000; Sandler et al, 2000; Thomas et al, 2002).
Changing the timing of administration along the 24-h time scale
can profoundly modify the extent of dose-limiting toxicities of
anticancer agents (Le ´vi, 1997, 2001). The adaptation of several
cancer chemotherapy regimens to circadian rhythms improved
their safety as well as their antitumour activity in patients
(Hrushesky, 1985; Le ´vi et al, 1997).
We investigated the relationship between the circadian rhythm
in the tolerability and the anticancer efficacy of gemcitabine in
mice, as a prerequisite for the development of chronotherapy
schedules with this drug in human cancer. Gemcitabine was first
given as a single agent, either as a single dose or according to a
repeat dosing schedule, previously shown to achieve good
tolerability and efficacy in mouse tumour models (Braakhuis
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set al, 1995). The effect of CDDP addition on gemcitabine was
further investigated as a function of dosing time.
MATERIAL AND METHODS
Animals and synchronisation
All experiments were carried out in accordance with the guidelines
for the welfare of animals in experimental neoplasia approved by
the UKCCCR (1998).
Male B6D2F1 mice bred by Charles River (l’Arbresle, France)
were 6 weeks of age upon arrival. They were housed two or three
per cage with food and water provided ad libitum. All mice were
synchronised with an alternation of 12h of light and 12h of
darkness for 3 weeks in an autonomous chronobiological animal
facility (Jouan, Saint-Herblain, France). The facility has six
soundproof, temperature-controlled compartments, each having
its own programmable lighting regimen. Each compartment was
constantly provided with filtered air delivered at an adjusted rate.
Synchronisation was checked by the assessment of a normal
circadian variation in the rectal temperature measured before
treatment initiation.
Tumour model
Glasgow osteosarcoma (GOS) was provided by the Research Centre
of Aventis Pharma (Vitry sur Seine, France). The tumour was
maintained in C57BL/6 female mice over 6 weeks of age and
passaged every 2 weeks as bilateral subcutaneous implants in
donor female C57BL/6 mice until the lower tumour weight reached
700mg.
Donor mice were killed, their tumour were removed, placed into
Hank’s balanced salt solution and dissected into fragments
measuring approximately 3 3mm
2 using a grill scaled to these
values. Recipient experimental mice were transplanted with one
tumour fragment in each flank, using a trocar. Bilateral implants
were used to ensure a more-uniform tumour burden per mouse.
Since the circadian time of tumour inoculation did not influence
tumour growth and survival of GOS-bearing mice (Granda et al,
2002), tumour was inoculated to all mice between 1000 and 1200
for chronoefficacy study.
The day of tumour transplantation was considered as day 0.
Tumours were measured every 2–3 days (length and width) with a
sliding caliper by the same investigator. Tumour weight was
calculated from caliper measurements using the following formula:
tumour weight (mg)¼(length width
2)/2. Animals with tumour
reaching 10% of initial mouse body weight along the course of the
study were killed by cervical dislocation for ethical reasons and
considered as dead from tumour progression on this day. The
number of days to reach this end point was used as a survival time
estimate.
Drugs
Gemcitabine were kindly provided by Eli Lilly (Indianapolis, IN,
USA). CDDP was purchased from Eli Lilly. Both were diluted in
0.9% NaCl on each study day and injected intravenously
(10mlkg
 1 of body weight) into the right retro-orbital venous
sinus. Control mice received 0.9% NaCl.
Study design
Chronotolerance Two experiments (Exp) were performed in a
total of 222 mice.
In Exp 1, gemcitabine (120, 160 or 200mgkg
 1injection
 1 – inj)
was given at one of six circadian times, expressed in hours after
light onset (HALO). Three, 7 and 11 HALO are located during the
light span, when mice are usually at rest, while 15, 19 and 23 HALO
correspond to the dark span, when mice are usually active. The
drug was injected every 3 days for 10 days to 144 mice. Lethal
toxicity and body weight were monitored daily for 14 days.
In Exp 2, gemcitabine (400mgkg
 1) was administered at 11 or
23 HALO, as a single agent or combined with CDDP (5mgkg
 1)t o
78 mice. CDDP was given 1min, 4h or 8h after gemcitabine. The
main end points were survival, body weight and circulating
neutrophil counts. For each mouse, blood (0.3ml) was collected at
5 HALO, a time corresponding to the physiologic acrophase of
circulating leukocytes, lymphocytes and neutrophils (Swoyer et al
1978) over the 6 days following drug dosing. Neutrophil count was
determined with Cell-Dyn (Abbott Diagnostics, Rungis, France).
Chronoefficacy
In Exp 3, single agent gemcitabine (200mgkg
 1inj
 1)o r
gemcitabine–cisplatin (200 and 5mgkg
 1inj
 1, respectively) were
given to mice with advanced GOS (600–800mg) at 11 or 23 HALO.
CDDP was given 1min or 4h after gemcitabine. The treatment was
delivered 10, 13, 16 and 19 days after tumour inoculation. Tumour
growth and survival were monitored for 90 days.
Statistical analysis
Mean71 s.e.m. were calculated for each variable. Differences
between groups were analysed with one- or two-way analysis of
variance (ANOVA). Survival curves were drawn according to
Kaplan–Meier, and differences in survival were tested using the
log-rank method. The time series data of body weight change were
further analysed by cosinor for 24 periodicity. This method
computes the mesor (midline estimating statistic of rhythm or
rhythm-adjusted mean), amplitude (half the difference between
maximum and minimum in fitted cosine function) and acrophase
(time of maximum in fitted cosine function). The 95% confidence
limits of these parameters were calculated. A value of Po0.05 was
required for statistical significance.
RESULTS
Chronotolerance
Multiple doses of single agent gemcitabine In Exp 1, three of 48
(6%) mice died from toxicity 11 or 12 days after treatment onset
with 200mgkg
 1inj
 1, as compared to none of the mice receiving
any lower dose. Lethal toxicity was only encountered following
gemcitabine administration at 19 HALO when it was 37.5% (three
out of eight), as compared to 0% in groups receiving the same
dose at any other time. Mean maximum body weight loss was
reached 1 day after the fourth dose and ranged from
1.170.4% (120mgkg
 1inj
 1) to 2.770.8% (160mgkg
 1inj
 1)
and 4.971.1% (200mgkg
 1inj
 1) (ANOVA P¼0.008). Irrespec-
tive of dose level, mean body weight loss varied from 7.471.9%
in the mice treated at 19 HALO, as compared to 0.170.4% in
those receiving gemcitabine at 11 HALO (Po0.001) (Figure 1A).
Furthermore, the dose–toxicity relation was much steeper if
gemcitabine was given at 19, 23 or 3 HALO as compared to 7, 11 or
15 HALO (Po0.001 for effects of dose and time) (Figure 1B). A
circadian rhythm in body weight change was further statistically
validated by cosinor analysis, with an acrophase corresponding to
the least toxic time which was located at 1030 HALO (95% CL, 800
to 1300) (P¼0.005).
Single dose of gemcitabine7CDDP
Body weight loss No lethal toxicity was encountered in Exp 2. The
average maximum weight loss following a single dose of
400mgkg
 1 of gemcitabine was reached 4 days after treatment.
It was 4.171.4% with gemcitabine alone and 7.470.6% with
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sgemcitabineþCDDP. Body weight loss was significantly less in the
mice given gemcitabine at 11 HALO as compared to 23 HALO,
whether gemcitabine was given alone or with CDDP, irrespective of
interval between both drugs (Table 1).
Haematological toxicity Neutropenia reached a nadir 3 days
following dosing, with full recovery 3 days later. The neutropenia
nadir was further decreased with CDDP addition. Interval between
gemcitabine and CDDP did not significantly influence neutropenia
(P from ANOVA¼0.55). However, neutropenia was more severe
following injection at 23 HALO as compared to 11 HALO, whether
gemcitabine was given alone or with CDDP (Pp0.001) (Table 1).
Effect of schedule of gemcitabine–CDDP combination
Recovery from weight loss following single dose of gemcitabine
combined with CDDP was influenced by gemcitabine dosing time
and the interval between both drugs. Combining both effects led to
contrast the worst schedule, consisting in the delivery of both
agents at 23 HALO from two ‘best’ schedules, consisting in the
administration of gemcitabine at 11 HALO and CDDP at 15 or 19
HALO (Figure 2). These findings were validated by two-way
ANOVA, which indicated statistically significant differences as
a function of both gemcitabine timing (P¼0.001) and interval
between the drugs (Po0.001).
Chronoefficacy of gemcitabine–CDDP No toxic death was
recorded after administration of gemcitabine alone in Exp 3. How-
ever, gemcitabine–CDDP induced 19 toxic deaths in 40 mice
(47.5%), 3–13 days following treatment completion. No mortality
was found in the mice given gemcitabine at 11 HALO then CDDP
at 15 HALO. Conversely, the rates of toxic death were 50% in mice
receiving gemcitabine at 23 HALO then CDDP at 4 HALO and
70% in those receiving gemcitabine and CDDP concurrently at 11
or 23 HALO (Fisher’s exact test P¼0.002).
The overall survival estimate of GOS-bearing mice was
prolonged from a median of 13 days in controls to 37 days in
mice given gemcitabine alone or 42 days in those receiving
gemcitabine–CDDP, irrespective of dosing time and interval
between both drugs (log rank Po0.001). No significant difference
was found between the groups given single agent gemcitabine at 11
or 23 HALO. Gemcitabine–CDDP combination proved of benefit
as compared to single agent gemcitabine. Such efficacy varied
significantly as a function of gemcitabine dosing time and
combination schedule. Median survival time estimate was
prolonged from 23 days in mice receiving gemcitabine at 23
HALO to 49 days in those receiving gemcitabine at 11 HALO,
irrespective of interval between gemcitabine and CDDP (log rank
P¼0.04). Median survival time estimate ranged from 22 or 24 days
following the concurrent delivery of gemcitabine and CDDP at 23
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Figure 1 Body weight change relative to pretreatment value
(mean7s.e.m.) in healthy B6D2F1 mice receiving gemcitabine (k) on days
1, 4, 7 and 10 at one of six circadian times. Circadian times are expressed in
hours after light onset (HALO). (A) Body weight change as a function of
gemcitabine timing over 2 weeks following treatment onset at one of three
dose levels (120, 160 or 200mgkg
 1inj
 1)( P from two-way ANO-
VAo0.001 for effects of dose and circadian time). (B) Body weight change
at nadir as a function of dose and dosing time.
Table 1 Body weight loss and extent of neutropenia at nadir according
to gemcitabine dosing time, whether the drug was given alone or combined
with CDDP in healthy mice, irrespective of interval between drugs
Gemcitabine
dosing time (HALO)
Toxicity Gemcitabine 11 23
Body weight loss (%) Single agent 1.970.7 6.472.4
Combined with CDDP 6.871.0 7.970.8
Neutrophil count (cellsmm
 3) Single agent 386724 250725
Combined with CDDP 365728 224728
Dosing times (HALO)
Gemcitabine      CDDP
11 15
11 19
23 7
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11 11
23 23
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Figure 2 Body weight change relative to pretreatment value
(mean7s.e.m.) in healthy mice over the week following a single treatment
with gemcitabine (400mgkg
 1) and CDDP (5mgkg
 1). Gemcitabine was
given at 11 or 23 HALO and CDDP was administered 1min, 4h or 8h
after eight gemcitabine timing (P from two-way ANOVA¼0.001 for
circadian time effect and o0.001 for interval effect).
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sor 11 HALO up to 68 days in the mice given gemcitabine at 11
HALO then CDDP at 15 HALO (log rank P¼0.02) (Figure 3).
DISCUSSION
Although the schedule dependency of gemcitabine has not been
fully investigated in humans, the weekly interval of gemcitabine
has been largely recommended in cancer patients. Twice weekly
administration of gemcitabine to patients showed a higher
incidence of non haematological toxicity, for example, flu-like
symptoms and rash and a lower dose intensity overall (Lund et al,
1993). On the basis of the schedule-dependent antitumour effect of
gemcitabine, the optimal time interval between bolus injections
was reported to be 3 days in mice (Lund et al, 1993; Kaye, 1994).
The toxicity for normal tissues was also reported to be reduced by
such 3-day interval between consecutive injections (Braakhuis
et al, 1995). The every 3 days 4 schedule, 120mgkg
 1inj
 1 on
days 1, 4, 7 and 10, produced a reversible weight loss of 5–15% in
tumour-bearing mice (Lund et al, 1993; Braakhuis et al, 1995). In
the present study, healthy mice receiving 120mgkg
 1inj
 1 hardly
lost any weight. Maximum body weight loss was less than 5%
following the administration of 160 or 200mgkg
 1inj
 1 4.
However, the tolerability of gemcitabine was several fold better
following dosing during the late light to early dark span (7–15
HALO) as compared to late darkness to early light (19–3 HALO).
Mean body weight loss was three-fold as large in the mice treated
with 200mgkg
 1inj
 1 at 19 HALO as compared to those receiving
gemcitabine between 7 and 15 HALO. According to cosinor
analysis, least gemcitabine toxicity corresponded to an adminis-
tration of this drug at 1030 HALO, in the late resting span of mice.
Subsequent experiments have compared overall and haematologi-
cal toxicities of gemcitabine as a function of whether the drug was
given at 11 HALO, close to the time of best tolerability, or at 23
HALO, close to the time of worst tolerability. These experiments
have clearly confirmed that gemcitabine administration at 11
HALO produced least body weight loss as compared to treatment
at 23 HALO, whether gemcitabine was given as a single agent or
combined with CDDP. Furthermore, the optimal interval between
gemcitabine and CDDP was 4 or 8h, in accordance with prior
reports (van Moorsel et al, 1999b, 2000). Our study has thus
identified an optimal combination schedule where gemcitabine is
given at 11 HALO and CDDP at 15 or 19 HALO, that is, the
respective times of least toxicity for each drug alone. The
haematological toxicity of gemcitabine was primarily exerted upon
neutrophil count. It was enhanced with CDDP addition and
reduced in the mice given gemcitabine at 11 HALO as compared to
23 HALO. This indicated that neutropenia was one of the
mechanisms of the dosing time dependent toxicity of gemcitabi-
ne7CDDP. Yet, the sparning of intestinal and lung toxicity with
gemcitabine timing could also contribute to circadian optimisa-
tion. Thus, both tissues represent toxicity targets for this drug and
display circadian rhythms in cellular proliferation and metabolism
(Scheving and Jin, 1999; Hastings et al, 2003).
Gemcitabine is an S-phase specific agent (Tolis et al, 1999) and
elicits apoptosis (Tolis et al, 1999; Giovannetti et al, 2005). This
process can be prevented by BCL-2 expression and favoured by
BAX expression (Hao et al, 2003). Indeed, the proportion of S-
phase cells in the bone marrow of the mouse, we used here was
highest in the second half of darkness, when locomotor activity
was highest (Tampellini et al, 1998; Filipski et al, 2004). As this
circadian stage, BAX expression was highest and BCL-2 expression
was low (Granda et al, 2005). The rhythms in S-phase distribution
and BCL-2/BAX expression are consistent with a better tolerability
of gemcitabine during the light span. Conversely, circadian
changes in S-phase and BCL-2 are usually markedly altered in
experimental tumours (Granda and Le ´vi, 2002; Granda et al, 2005).
The deregulation of G1–S checkpoint control by the circadian
clock can relate to altered clock gene expression patterns in
the tumour, as it was found for GOS (Filipski et al, 2004,
2005). Conversely, the circadian control of G2–M checkpoint
appears to be maintained in most experimental malignances, a
finding consistent with the circadian dependency of CDDP or
oxaliplatin antitumour activity (Granda and Le ´vi, 2002; Granda
et al, 2002, 2005).
The higher dose level of gemcitabine (200mgkg
 1inj
 1) was
used here to investigate the circadian dependency of antitumour
efficacy, since no toxic death was uncounted and mean body
weight loss was less 10% following dosing at 11 or 23 HALO. In
mice bearing GOS at advanced stage of growth, we first confirmed
the better efficacy of gemcitabine–CDDP over gemcitabine alone.
We further found that the delivery of gemcitabine at 11 HALO and
CDDP at 15 HALO increased median survival three-fold, as
compared with other schedules. The results support that a
synergistic activity of these drugs requires their administration
near their respective ‘best’ circadian times. They are in line with
the coincidence between the time of best efficacy and that of best
tolerability, which was recently shown for single agent doxo-
rubicin, docetaxel or vinorelbine and for docetaxel–doxorubicin
or irinotecan–oxaliplatin combination (Tampellini et al, 1998;
Filipski et al, 1999; Granda et al, 2001, 2002). Although we have not
explored the relevance of this best treatment schedule in
other host or tumour models, we believe that our findings
support the administration of gemcitabine at 11 HALO then
CDDP at 15 HALO. Similar circadian patterns have been shown
for the chronopharmacology of anticancer drugs across
different rodent species or strains (Granda and Le ´vi, 2002).
Mechanisms include rhythms in reduced glutathione content in
liver and other organs and host tolerability for platinum complexes
in rats and mice (Be ´langer et al, 1988; Li et al, 1997) and
rhythms in BCL-2 expression in bone marrow and host tolera-
bility for docetaxel in B6D2F1 and C3H/He mice (Tampellini
et al, 1998; Granda et al, 2001, 2005). A similar circadian pattern
in the anticancer efficacy of the same drug has also been
shown in different experimental tumour models (Granda and
Le ´vi, 2002). For instance, platinum complexes were most active
against rat plasmacytoma or mouse osteosarcoma following
dosing near the middle of the night (Sothern et al, 1989; Granda
et al, 2002), while docetaxel was most active against mammary
MA13/C or pancreatic P03 carcinomas following dosing at
daytime in mice from different strains (Tampellini et al, 1998;
Granda et al, 2001).
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Figure 3 Survival curves of GOS-bearing mice receiving gemcitabine
(200mgkg
 1inj
 1) combined with CDDP (5mgkg
 1inj
 1) 10, 13, 16 and
19 after tumour inoculation. Gemcitabine was given at 11 or 23 HALO and
CDDP was injected 1min or 4h after gemcitabine timing (P from log
rank¼0.02). BW: body weight.
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sThe optimal circadian times for the delivery of gemcitabine and
CDDP correspond to awakening and mid-activity in cancer
patients, two circadian stages that can be identified with rest-
activity monitoring, using a wrist-worn watch for 3–7 days
(Mormont et al, 2000).
Thus, the rest-activity rhythm is the most overt output of the
circadian timing system in mammals (Hastings et al,2 0 0 3 ) .M a n y
other rhythmic biologic functions that are relevant for the
chronopharmacology of anticancer agents display a similar phase
relation with the rest-activity rhythm both in rodents and in
humans. These observations have led to refer the optimal treatment
times to the onset of the rest phase of the rest-activity cycle (Le ´vi,
2001). For instance, dosing oxaliplatin near 1600 and 5-fluorouracil
near 0400 proved to be a better schedule than constant rate infusion
of the same drugs in a phase III trial of this combination in patients
with metastatic colorectal cancer (Le ´vi et al, 1997). Another clinical
trial with this combination has further confirmed these times as
being best as compared to seven other ones staggered along the 24-h
time scale (Le ´vi et al,i np r e p a r a t i o n ) .
Nevertheless, the circadian pattern in rest-activity was altered in
one-third of patients with metastatic cancer. Furthermore, the
‘strength’ of the circadian component of the rest-activity rhythm
displayed both a close relation with quality of life and an
independent prognostic value for survival (Mormont et al, 2000;
Innominato et al, 2005; Garufi et al, 2005). While the relevance of
this rhythm for the prediction of chronotherapy efficacy is
currently being investigated, we feel that rest-activity monitoring
should be performed prior to the delivery of gemcitabine–CDDP
chronotherapy. Presumably, a 2.5h duration should be preferential
for gemcitabine infusion (Tempero et al, 2003).
Such clinical chronopharmacologic development of gemcita-
bine-platinum combination is warranted in view of both the
limited efficacy of current treatment regimens in advanced lung
cancer and the three-fold survival benefit achieved here by the
optimal circadian schedule as compared to concurrent dosing of
both agents in the experimental model.
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